BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24710929)

  • 1. Expression of cancer-testis antigen in multiple myeloma.
    He L; Ji JN; Liu SQ; Xue E; Liang Q; Ma Z
    J Huazhong Univ Sci Technolog Med Sci; 2014 Apr; 34(2):181-185. PubMed ID: 24710929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.
    Taylor BJ; Reiman T; Pittman JA; Keats JJ; de Bruijn DR; Mant MJ; Belch AR; Pilarski LM
    J Immunother; 2005; 28(6):564-75. PubMed ID: 16224274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.
    de Carvalho F; Alves VL; Braga WM; Xavier CV; Colleoni GW
    Cancer Immunol Immunother; 2013 Jan; 62(1):191-5. PubMed ID: 23180015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
    de Carvalho F; Costa ET; Camargo AA; Gregorio JC; Masotti C; Andrade VC; Strauss BE; Caballero OL; Atanackovic D; Colleoni GW
    PLoS One; 2011; 6(11):e27707. PubMed ID: 22110734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.
    de Carvalho F; Vettore AL; Colleoni GW
    Clin Dev Immunol; 2012; 2012():257695. PubMed ID: 22481966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation.
    Jungbluth AA; Ely S; DiLiberto M; Niesvizky R; Williamson B; Frosina D; Chen YT; Bhardwaj N; Chen-Kiang S; Old LJ; Cho HJ
    Blood; 2005 Jul; 106(1):167-74. PubMed ID: 15761016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of multiple cancer-testis antigen genes in non-small cell lung cancer treated by chemotherapy prior surgery].
    Wang Y; Liang Z; Yuan YH; Han Y; Liu YX; Liu N; Chen YT; Ritter G; Old LJ; Zhang LJ
    Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(6):464-8. PubMed ID: 15061963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
    Pabst C; Zustin J; Jacobsen F; Luetkens T; Kröger N; Schilling G; Bokemeyer C; Sauter G; Atanackovic D; Marx A
    Exp Mol Pathol; 2010 Oct; 89(2):175-81. PubMed ID: 20621094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.
    Lendvai N; Gnjatic S; Ritter E; Mangone M; Austin W; Reyner K; Jayabalan D; Niesvizky R; Jagannath S; Bhardwaj N; Chen-Kiang S; Old LJ; Cho HJ
    Cancer Immun; 2010 Jan; 10():4. PubMed ID: 20108890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
    Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
    Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7.
    Jungbluth AA; Antonescu CR; Busam KJ; Iversen K; Kolb D; Coplan K; Chen YT; Stockert E; Ladanyi M; Old LJ
    Int J Cancer; 2001 Oct; 94(2):252-6. PubMed ID: 11668506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.
    Atanackovic D; Hildebrandt Y; Jadczak A; Cao Y; Luetkens T; Meyer S; Kobold S; Bartels K; Pabst C; Lajmi N; Gordic M; Stahl T; Zander AR; Bokemeyer C; Kröger N
    Haematologica; 2010 May; 95(5):785-93. PubMed ID: 20015885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.
    Zimmermann AK; Imig J; Klar A; Renner C; Korol D; Fink D; Stadlmann S; Singer G; Knuth A; Moch H; Caduff R
    Virchows Arch; 2013 May; 462(5):565-74. PubMed ID: 23529156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SSX expression in gynecological cancers and antibody response in patients.
    Hasegawa K; Koizumi F; Noguchi Y; Hongo A; Mizutani Y; Kodama J; Hiramatsu Y; Nakayama E
    Cancer Immun; 2004 Dec; 4():16. PubMed ID: 15603546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SSX: a multigene family with several members transcribed in normal testis and human cancer.
    Gure AO; Türeci O; Sahin U; Tsang S; Scanlan MJ; Jäger E; Knuth A; Pfreundschuh M; Old LJ; Chen YT
    Int J Cancer; 1997 Sep; 72(6):965-71. PubMed ID: 9378559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.
    Dhodapkar MV; Osman K; Teruya-Feldstein J; Filippa D; Hedvat CV; Iversen K; Kolb D; Geller MD; Hassoun H; Kewalramani T; Comenzo RL; Coplan K; Chen YT; Jungbluth AA
    Cancer Immun; 2003 Jul; 3():9. PubMed ID: 12875607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.
    Wen J; Li H; Tao W; Savoldo B; Foglesong JA; King LC; Zu Y; Chang CC
    Br J Haematol; 2014 Sep; 166(5):711-9. PubMed ID: 24889268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.
    Atanackovic D; Arfsten J; Cao Y; Gnjatic S; Schnieders F; Bartels K; Schilling G; Faltz C; Wolschke C; Dierlamm J; Ritter G; Eiermann T; Hossfeld DK; Zander AR; Jungbluth AA; Old LJ; Bokemeyer C; Kröger N
    Blood; 2007 Feb; 109(3):1103-12. PubMed ID: 17023585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of molecular and cytogenetic findings in synovial sarcoma.
    Panagopoulos I; Mertens F; Isaksson M; Limon J; Gustafson P; Skytting B; Akerman M; Sciot R; Dal Cin P; Samson I; Iliszko M; Ryoe J; Dêbiec-Rychter M; Szadowska A; Brosjö O; Larsson O; Rydholm A; Mandahl N
    Genes Chromosomes Cancer; 2001 Aug; 31(4):362-72. PubMed ID: 11433527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.
    Andrade VC; Vettore AL; Felix RS; Almeida MS; Carvalho F; Oliveira JS; Chauffaille ML; Andriolo A; Caballero OL; Zago MA; Colleoni GW
    Cancer Immun; 2008 Feb; 8():2. PubMed ID: 18237105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.